174 related articles for article (PubMed ID: 24492290)
1. Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use.
Stevens MW; Tawney RL; West CM; Kight AD; Henry RL; Owens SM; Gentry WB
MAbs; 2014; 6(2):547-55. PubMed ID: 24492290
[TBL] [Abstract][Full Text] [Related]
2. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
[TBL] [Abstract][Full Text] [Related]
3. Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period.
Hambuchen MD; Rüedi-Bettschen D; Williams DK; Hendrickson H; Owens SM
Vaccine; 2014 Oct; 32(47):6213-9. PubMed ID: 25252196
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological effects of two anti-methamphetamine monoclonal antibodies. Supporting data for lead candidate selection for clinical development.
Laurenzana EM; Stevens MW; Frank JC; Hambuchen MD; Hendrickson HP; White SJ; Williams DK; Owens SM; Gentry WB
Hum Vaccin Immunother; 2014; 10(9):2638-47. PubMed ID: 25483484
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment of (+)-methamphetamine-induced locomotor effects in rats using one or a combination of two high affinity anti-methamphetamine monoclonal antibodies.
Hambuchen MD; Rüedi-Bettschen D; Gunnell MG; Hendrickson H; Owens SM
Hum Vaccin Immunother; 2016 Sep; 12(9):2240-8. PubMed ID: 27163775
[TBL] [Abstract][Full Text] [Related]
6. The anti-(+)-methamphetamine monoclonal antibody mAb7F9 attenuates acute (+)-methamphetamine effects on intracranial self-stimulation in rats.
Harris AC; LeSage MG; Shelley D; Perry JL; Pentel PR; Owens SM
PLoS One; 2015; 10(3):e0118787. PubMed ID: 25742165
[TBL] [Abstract][Full Text] [Related]
7. Combining Active Immunization with Monoclonal Antibody Therapy To Facilitate Early Initiation of a Long-Acting Anti-Methamphetamine Antibody Response.
Hambuchen MD; Carroll FI; Rüedi-Bettschen D; Hendrickson HP; Hennings LJ; Blough BE; Brieaddy LE; Pidaparthi RR; Owens SM
J Med Chem; 2015 Jun; 58(11):4665-77. PubMed ID: 25973614
[TBL] [Abstract][Full Text] [Related]
8. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats.
Laurenzana EM; Byrnes-Blake KA; Milesi-Hallé A; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2003 Nov; 31(11):1320-6. PubMed ID: 14570763
[TBL] [Abstract][Full Text] [Related]
9. Vaccination protects rats from methamphetamine-induced impairment of behavioral responding for food.
Rüedi-Bettschen D; Wood SL; Gunnell MG; West CM; Pidaparthi RR; Carroll FI; Blough BE; Owens SM
Vaccine; 2013 Sep; 31(41):4596-602. PubMed ID: 23906885
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a monoclonal antibody against methamphetamine and amphetamine reduces maternal and fetal rat brain concentrations in late pregnancy.
White SJ; Hendrickson HP; Atchley WT; Laurenzana EM; Gentry WB; Williams DK; Owens SM
Drug Metab Dispos; 2014 Aug; 42(8):1285-91. PubMed ID: 24839971
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficiency of an anti-(+)-methamphetamine monoclonal antibody in the protection against cardiovascular and central nervous system effects of (+)-methamphetamine in rats.
Gentry WB; Laurenzana EM; Williams DK; West JR; Berg RJ; Terlea T; Owens SM
Int Immunopharmacol; 2006 Jun; 6(6):968-77. PubMed ID: 16644483
[TBL] [Abstract][Full Text] [Related]
12. PEGylation of a High-Affinity Anti-(+)Methamphetamine Single Chain Antibody Fragment Extends Functional Half-Life by Reducing Clearance.
Reichard EE; Nanaware-Kharade N; Gonzalez GA; Thakkar S; Owens SM; Peterson EC
Pharm Res; 2016 Dec; 33(12):2954-2966. PubMed ID: 27620175
[TBL] [Abstract][Full Text] [Related]
13. Development of active and passive human vaccines to treat methamphetamine addiction.
Gentry WB; Rüedi-Bettschen D; Owens SM
Hum Vaccin; 2009 Apr; 5(4):206-13. PubMed ID: 19276653
[TBL] [Abstract][Full Text] [Related]
14. Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats.
Byrnes-Blake KA; Carroll FI; Abraham P; Owens SM
Int Immunopharmacol; 2001 Feb; 1(2):329-38. PubMed ID: 11360933
[TBL] [Abstract][Full Text] [Related]
15. Using hapten design to discover therapeutic monoclonal antibodies for treating methamphetamine abuse.
Peterson EC; Gunnell M; Che Y; Goforth RL; Carroll FI; Henry R; Liu H; Owens SM
J Pharmacol Exp Ther; 2007 Jul; 322(1):30-9. PubMed ID: 17452421
[TBL] [Abstract][Full Text] [Related]
16. A Nanotechnology-Based Platform for Extending the Pharmacokinetic and Binding Properties of Anti-methamphetamine Antibody Fragments.
Nanaware-Kharade N; Thakkar S; Gonzalez GA; Peterson EC
Sci Rep; 2015 Jul; 5():12060. PubMed ID: 26159352
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines.
Duryee MJ; Bevins RA; Reichel CM; Murray JE; Dong Y; Thiele GM; Sanderson SD
Vaccine; 2009 May; 27(22):2981-8. PubMed ID: 19428909
[TBL] [Abstract][Full Text] [Related]
18. Customizing monoclonal antibodies for the treatment of methamphetamine abuse: current and future applications.
Peterson EC; Gentry WB; Owens SM
Adv Pharmacol; 2014; 69():107-27. PubMed ID: 24484976
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies as pharmacokinetic antagonists for the treatment of (+)-methamphetamine addiction.
Owens SM; Atchley WT; Hambuchen MD; Peterson EC; Gentry WB
CNS Neurol Disord Drug Targets; 2011 Dec; 10(8):892-8. PubMed ID: 22229314
[TBL] [Abstract][Full Text] [Related]
20. Development and preclinical testing of a high-affinity single-chain antibody against (+)-methamphetamine.
Peterson EC; Laurenzana EM; Atchley WT; Hendrickson HP; Owens SM
J Pharmacol Exp Ther; 2008 Apr; 325(1):124-33. PubMed ID: 18192498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]